ArticleClinical epidemiology2025
Risk Signals of Antibody-Drug Conjugates in Bladder Cancer: A Real-World FAERS Study.
Article in Clinical epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Infectious Complications of Antibody-Drug Conjugates: A Review of Safety Data from FDA-Approved Agents.Current oncology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibody-drug conjugates (ADCs) represent a transformative class of therapeutics for advanced bladder cancer. However, their real-world safety profiles are not yet fully characterized. Methods: This retrospective pharmacovigilance study analyzed data from the FDA Adverse Event Reporting System (FAERS) from the first quarter of 2004 to the third quarter of 2024. Disproportionality analyses, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN), were used to detect significant adverse drug event (ADE) signals for four ADCs in bladder cancer treatment: enfortumab vedotin (EV), sacituzumab govitecan (SG), trastuzumab deruxtecan (DS-8201), and trastuzumab emtansine (T-DM1). Results: Among 494 analyzed reports, EV constituted the majority (91.7%). Distinct safety signals were identified for each ADC: EV was strongly associated with skin disorders and metabolic disturbances; SG was primarily linked to gastrointestinal events, with emerging signals of renal abnormalities; DS-8201 was associated with systemic administration-related issues; and T-DM1 showed signals for respiratory and bleeding events. Notably, oral candidiasis related to EV was not explicitly highlighted in the current prescribing information. Conclusion: This study delineates the safety profiles of ADC therapies for bladder cancer, confirming known risks and identifying potential new signals. The findings highlight the need for ADC-specific monitoring strategies and proactive management protocols to mitigate toxicities, thereby providing essential evidence for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.